Literature DB >> 32558286

Double filtration plasmapheresis: Review of current clinical applications.

Ryuichiro Hirano1, Kenichiro Namazuda1, Noriko Hirata1.   

Abstract

Double filtration plasmapheresis (DFPP) is a semi-selective blood purification modality derived from the plasma exchange (PE) modality. In the DFPP treatment, two types of filters with different pore sizes are used: a plasma separator and a plasma component separator. Blood is separated into plasma and blood cells using a plasma separator. The separated plasma is fractionated into large and small molecular weight components by a plasma component separator. Large molecular weight components, including pathogenic substances, are discarded. Small molecular weight components, including valuable substances such as albumin, are returned to the patient. The advantage of DFPP is that the volume of replacement fluid can be significantly reduced compared to PE. By selecting the optimal pore size model for the plasma component separator, DFPP can be applied to various disorders. The clinical applications of DFPP are reviewed based on recent articles on metabolic disorders, organ transplants, rheumatic disorders, neurological disorders, and dermatologic disorders.
© 2020 International Society for Apheresis, Japanese Society for Apheresis, and Japanese Society for Dialysis Therapy.

Entities:  

Keywords:  double filtration plasmapheresis; plasma component separator; plasma fractionator; semi-selective

Year:  2020        PMID: 32558286     DOI: 10.1111/1744-9987.13548

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  4 in total

Review 1.  Therapeutic apheresis in kidney diseases: an updated review.

Authors:  Yi-Yuan Chen; Xin Sun; Wei Huang; Fang-Fang He; Chun Zhang
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

2.  Changes in Water Properties in Human Tissue after Double Filtration Plasmapheresis-A Case Study.

Authors:  Felix Scholkmann; Roumiana Tsenkova
Journal:  Molecules       Date:  2022-06-20       Impact factor: 4.927

3.  Difficult Journey to Find the Best Treatment for Homozygous Familial Hypercholesterolemia: Case Report.

Authors:  Ming-Jun Xu; Jian-Ping Chu; Wen-Ling Fei; Juan Wang; Yan-Min Zhang; Yi Wang
Journal:  Int Med Case Rep J       Date:  2022-03-21

4.  Case report: Successful combination therapy with double-filtration plasmapheresis and rituximab under the condition of the use of a sensor-augmented pump for type B insulin resistance syndrome.

Authors:  Arata Osanami; Masatoshi Kanda; Tatsuya Sato; Chikako Akazawa; Shuhei Baba; Hiroaki Komatsu; Kazuyuki Murase; Tomohisa Yamashita; Toshiyuki Yano
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-09       Impact factor: 6.055

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.